Clinical Trials in Austin

Showing 2441-2460 of 7,312 trials

Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS

NCT05196828

Multi-center, prospective open-label extension study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate- severe primary RLS

Restless Legs Syndrome

Noctrix Health, Inc.103 participantsStarted Dec 2021

San Leandro, California, United States • Colorado Springs, Colorado, United States • Atlanta, Georgia, United States +4 more locations

COMPLETEDPhase 1< 1 mile

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

NCT05291520

An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.

HIV Infections

ViiV Healthcare24 participantsStarted Feb 2022

Austin, Texas, United States

COMPLETEDPhase 1/2< 1 mile

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

NCT04909450

This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.

Neurotrophic Keratitis

Claris Biotherapeutics, Inc.131 participantsStarted Aug 2021

Cave Creek, Arizona, United States • Loma Linda, California, United States • Los Angeles, California, United States +45 more locations

Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Find Trials by Condition in Austin

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

The PREDICT Registry:

A Safety and Efficacy Study in Patients With Gastric Cancer

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

International Weight Control Registry

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry